Inotek Pharmaceuticals Corporation

Harvard College

The Brigham and Women's Hospital, Inc.

Radikal Therapeutics Inc.

Cincinnati Children's Hospital Medical Center

Inotek Corporation

Salzman Group, Inc.

Inotek Pharmaceutical Corporation

Prakash Jagtap

Csaba Szabo

Andrew L Salzman

Garry Southan

Gregory D Cuny

Junying Yuan

Alexei Degterev

Andrew Lurie Salzman

William K McVicar

Thomas Mccauley

Norman N Kim

John Henry Van Duzer

Erkan Baloglu

Siya Ram

William Williams, Iii

Yi Zheng

Jaroslaw Meller

Aloka Roy

Emily E Bosco

Duy-Phong Pham-Huu

Marie-Dominique Filippi

Xiaojing Wang

Frederick Cohen

Junichi Hitomi

Gary Southan

Garry John Southan

A method reduces oxidative stress or endothelial dysfunction in a mammal. The method includes administering to the mammal a compound of formula I: or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt of the compound.

Method for treating diseases associated with oxidative stress or endothelial dysfunction using substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds

Compounds are of the class of 1-pyrrolidinyloxy,1-piperidinyloxy, and 1-azepanyloxy derivatives of formula (I): The compounds are useful in prevention, treatment or management of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction. The compounds include 2,2,5,5,-tetramethyl-3-(nitrooxymethyl)pyrrolidin-1-yl acetate.

Substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds for treating diseases associated with oxidative stress or endothelial dysfunction

Inhibitors of p67protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.

[object Object]

Multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ROS) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them are provided. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.

Multifunctional nitroxide derivatives and uses thereof

Inhibitors of p67protein are provided herein, as well as pharmaceutical compositions and methods recited thereto.

Use of small molecule inhibitors targeting the interaction between Rac GTPase and p67 (phox)

Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).

Method of reducing intraocular pressure in humans

The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.

Inhibitors of cellular necrosis

The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

Purine derivatives as adenosine A1 receptor agonists and methods of use thereof

Provided herein are a class of purine nucleoside compounds, particularly substituted adenosine compounds, such as benzyloxy cyclopentyladenosine (BCPA) compounds, as well as methods of using these compounds as selective Aadenosine receptor agonists, particularly for reducing and/or controlling elevated or abnormally fluctuating intraocular pressure (IOP) in the treatment of glaucoma or ocular hypertension (OHT).

Adenosine compounds and their use thereof

The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described.

Tricyclic necrostatin compounds

Growing community of inventors

North Andover, MA, United States of America

Prakash Jagtap